Evaluation of adverse effects of lamotrigine–tramadol combination with special reference to biochemical safety parameters in albino rats. An experimental study.
DOI:
https://doi.org/10.51168/sjhrafrica.v6i12.2489Keywords:
Lamotrigine, Tramadol, Biochemical safety, Albino rats, Adverse effectsAbstract
Background
Lamotrigine and tramadol are frequently used drugs for neuropathic and chronic pain conditions. While both drugs are effective individually, data on their combined safety profile remain limited.
Objective
To evaluate the adverse effects of lamotrigine–tramadol combination with special reference to biochemical safety parameters along with pharmacological assessment.
Materials and Methods.
Thirty albino rats were divided into five groups (n=6). Drugs were administered orally for 28 days. Analgesic activity was evaluated using tail clip and formalin tests. Biochemical parameters including liver enzymes, renal markers, and oxidative stress markers were assessed. Statistical analysis was done using one-way ANOVA followed by Tukey’s test.
Results
Combination therapy showed significantly higher analgesic activity (p<0.05) compared to individual drugs. Mild but statistically significant elevations in liver enzymes and oxidative stress markers were observed.
Conclusion
Lamotrigine tramadol combination enhances analgesic efficacy but produces mild biochemical alterations, warranting cautious use.
Recommendation:
The lamotrigine–tramadol combination may be used for enhanced analgesic efficacy; however, periodic monitoring of liver enzymes and oxidative stress markers is recommended during prolonged therapy.
References
Woolf CJ. Pain: Moving from symptom control toward mechanism-specific pharmacologic management. Nature. 2011;477:436–442.
Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin Pharmacokinet. 2004;43:879–923.
Chew ML, Mulsant BH, Pollock BG, et al. Anticonvulsants for neuropathic pain and psychiatric disorders. Drugs. 2000;60:1–34.
Backonja M. Use of anticonvulsants for treatment of neuropathic pain. Neurology. 2002;59:S14–S17.
Gilron I, Baron R, Jensen T. Neuropathic pain: Principles of diagnosis and treatment. N Engl J Med. 2015;372:109–119.
Rang HP, Ritter JM, Flower RJ, Henderson G. Rang and Dale’s Pharmacology. 8th ed. London: Elsevier; 2016.
Katzung BG, Trevor AJ. Basic and Clinical Pharmacology. 14th ed. New York: McGraw Hill; 2018.
Talaie H, Panahandeh R, Fayaznouri M, Asadi Z, Abdollahi M. Dose-independent occurrence of seizure with tramadol. Toxicol Mech Methods. 2009;19:123–126.
Labate A, Gambardella A, Andermann E, Aguglia U. Tramadol-induced seizures. Epilepsia. 2006;47:163–165.
Chang CC, Chen YC, Wang JD. Lamotrigine-induced hepatotoxicity: A review. Drug Saf. 2012;35:469–484.
Turner PV, Pekow C, Vasbinder MA, Brabb T. Administration of substances to laboratory animals. ILAR J. 2011;52:243–254.
Halliwell B. Oxidative stress and cancer: Have we moved forward? Free Radic Biol Med. 2007;43:1–14.
Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions. Int J Biochem Cell Biol. 2007;39:44–84.
Gilron I. Combination pharmacotherapy for neuropathic pain. Pain. 2013;154:S1–S2.
Smith HS. Combination opioid–anticonvulsant therapy for neuropathic pain. Pain Physician. 2008;11:S133–S153.
Zeng C, Dubreuil M, LaRochelle MR, et al. Association of tramadol with adverse outcomes. Pain Pract. 2019;19:345–356.
Dubuisson D, Dennis SG. The formalin test: A quantitative study of nociceptive responses. Pain. 1977;4:161–174.
Li Y, Zhou Y, Wang H. Tramadol-induced oxidative stress and hepatotoxicity in rats. Toxicol Lett. 2013;222:53–60.
Reuben SS. Opioid-related adverse drug reactions. Anesth Analg. 2007;105:184–190.
Navarro VJ, Senior JR. Drug-related hepatotoxicity. N Engl J Med. 2006;354:731–739.
Kisaoglu A, Borekci B, Yapca OE, et al. Oxidative stress and drug-induced toxicity. Biomed Res Int. 2013;2013:1–6.
Abdel-Zaher AO, Abdel-Rahman MS, Elwasei FM. Protective effect of antioxidants against tramadol toxicity. Toxicol Lett. 2010;195:159–167.
Chawla LS, Kimmel PL. Acute kidney injury and drug safety. Kidney Int. 2014;86:130–138.
Brunton LL, Hilal-Dandan R, Knollmann BC. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 13th ed. New York: McGraw Hill; 2018.
Katz NP, Birnbaum H, Brennan MJ, et al. Prescription opioid abuse: Challenges and solutions. Clin J Pain. 2011;27:486–497.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Dr. Shashi kala Kumari, Ravi Kant, Sushma Kumari
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
